Baird Starts Cogent (COGT) at Outperform, Says '$16/share of our $20 price target to bezuclastinib for non-advanced SM'
Tweet Send to a Friend
(Updated - April 28, 2023 8:35 AM EDT)
Baird analyst Joel Beatty initiates coverage on Cogent (NASDAQ: COGT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst Joel Beatty initiates coverage on Cogent (NASDAQ: COGT) with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
